account_balance
Investment manager · 13F filer · SEC CIK 1121404
Sanofi
Reported value$630Mas of Sep 30, 2026
Positions16 6 new, 0 sold out
Top 10 weight92.1%MGTX alone is 21%
FiledNov 536 days after quarter end
Portfolio · as of Sep 30, 2026
Where the money is
New or addedTrimmedHeld
MGTXMeiraGTx Holdings PLC
21.3%
INBXInhibrx Biosciences, Inc.
18.4%
NVAXNovavax
11.8%
KRSAKorsana Biosciences
10.1%New
ODTXOdyssey Therapeutics Inc.
7.0%
ANABAnaptysBio
6.6%
AGMBAgomab Therapeutics NV
4.9%
TRAXFirst Tracks Biotherapeutics Inc.
4.6%
ETRAElectra Therapeutics Inc
4.4%New
ATTOAttovia Therapeutics Inc
2.9%New
LTGO1.8%IMRX1.8%MGTXMeiraGTx Holdings PLC
21.3%
INBXInhibrx Biosciences, Inc.
18.4%
NVAXNovavax
11.8%
KRSAKorsana Biosciences
10.1%New
ODTX7.0%ANAB6.6%AGMB4.9%TRAX4.6%ETRA4.4%ATTOLTGO1.8%IMRX1.8%Boxes show the top 12 stocks, sized against each other. The bar above shows how much of the fund they are. 13F only covers US-listed stocks, so foreign holdings and short positions are missing.
Show the top 12 as a list
MGTX MeiraGTx Holdings PLC 21.3% HeldINBX Inhibrx Biosciences, Inc. 18.4% HeldNVAX Novavax 11.8% HeldKRSA Korsana Biosciences 10.1% NewODTX Odyssey Therapeutics Inc. 7.0% HeldANAB AnaptysBio 6.6% HeldAGMB Agomab Therapeutics NV 4.9% HeldTRAX First Tracks Biotherapeutics Inc. 4.6% HeldETRA Electra Therapeutics Inc 4.4% NewATTO Attovia Therapeutics Inc 2.9% NewLTGO Latigo Biotherapeutics Inc 1.8% NewIMRX Immuneering Corp 1.8% Held
What changed